On September 8, 2020 Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon), reported that they will present data from the TEM-GBM study at the Advanced Therapies Congress & Expo 2020 (Press release, Genenta Science, SEP 8, 2020, View Source [SID1234568502]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Carlo Russo, Chief Medical Officer and Head of Development at Genenta, will provide an overview of Temferon, the company’s pipeline and the latest preliminary clinical data in patients affected with glioblastoma multiforme, on September 9, at 6.50pm CET.